As of 2026-01-05, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -22.51. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 777.10 mil USD. TBPH's TTM EBITDA according to its financial statements is -34.53 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.7x - 8.4x | 5.7x |
| Forward P/E multiples | 5.2x - 7.1x | 6.2x |
| Fair Price | (0.72) - (2.00) | (1.24) |
| Upside | -103.9% - -111.0% | -106.8% |
| Date | EV/EBITDA |
| 2026-01-02 | -22.51 |
| 2025-12-31 | -23.33 |
| 2025-12-30 | -23.62 |
| 2025-12-29 | -23.33 |
| 2025-12-26 | -23.52 |
| 2025-12-24 | -23.36 |
| 2025-12-23 | -23.12 |
| 2025-12-22 | -23.48 |
| 2025-12-19 | -23.45 |
| 2025-12-18 | -22.55 |
| 2025-12-17 | -22.16 |
| 2025-12-16 | -21.60 |
| 2025-12-15 | -21.95 |
| 2025-12-12 | -22.54 |
| 2025-12-11 | -21.82 |
| 2025-12-10 | -21.72 |
| 2025-12-09 | -22.01 |
| 2025-12-08 | -22.46 |
| 2025-12-05 | -23.09 |
| 2025-12-04 | -23.31 |
| 2025-12-03 | -23.59 |
| 2025-12-02 | -22.92 |
| 2025-12-01 | -24.65 |
| 2025-11-28 | -25.66 |
| 2025-11-26 | -25.16 |
| 2025-11-25 | -23.67 |
| 2025-11-24 | -23.02 |
| 2025-11-21 | -22.99 |
| 2025-11-20 | -22.14 |
| 2025-11-19 | -21.89 |
| 2025-11-18 | -23.01 |
| 2025-11-17 | -22.35 |
| 2025-11-14 | -21.39 |
| 2025-11-13 | -22.21 |
| 2025-11-12 | -21.96 |
| 2025-11-11 | -23.02 |
| 2025-11-10 | -18.00 |
| 2025-11-07 | -17.52 |
| 2025-11-06 | -17.69 |
| 2025-11-05 | -17.81 |
| 2025-11-04 | -17.52 |
| 2025-11-03 | -18.21 |
| 2025-10-31 | -17.39 |
| 2025-10-30 | -16.86 |
| 2025-10-29 | -16.67 |
| 2025-10-28 | -16.56 |
| 2025-10-27 | -16.86 |
| 2025-10-24 | -16.83 |
| 2025-10-23 | -16.62 |
| 2025-10-22 | -16.42 |